← All organizations
Highest phase reached
Phase 2
First clinical trial
Jan 1, 2001Last known activity
May 12, 2025
Timeline
2000s
- Jan 1, 2001
Institute for Neurodegenerative Disorders— Founded
Drugs by trial phase (42 distinct, 46 trials)
Phase 2 (11 own, 0 via acquisition)
Phase 1 (28 own, 0 via acquisition)
Other trials (3 own, 0 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Aphasia, Primary Progressive
- Autism Spectrum Disorder
- Autistic Disorder
- Brain Diseases
- Brain Injuries, Traumatic
- Chronic Traumatic Encephalopathy
- Cognitive Dysfunction
- Dementia
- Fragile X Syndrome
- Frontotemporal Dementia
- Huntington Disease
- Inflammation
- Multiple Sclerosis
- Neurodegenerative Diseases
- Parkinson Disease
- Pick Disease of the Brain
- Sclerosis
- Supranuclear Palsy, Progressive
- Syndrome
- Tauopathies
Recent trials (50)
- NCT07020026OfficialPhase 2May 12, 2025
- NCT07020026CollaboratorPhase 2May 12, 2025
- NCT07265596OfficialPhase 2Oct 30, 2023
- NCT04906590CollaboratorPhase 2Aug 30, 2021
- NCT02370524Overall official - principal investigatorPhase 1Jan 1, 2015
- NCT02370524CollaboratorPhase 1Jan 1, 2015
- NCT02103894CollaboratorPhase 1Feb 1, 2014
- NCT02103894Overall official - principal investigatorPhase 1Feb 1, 2014
- NCT01767493Reponsible party - principal investigatorN/ANov 1, 2012
- NCT01767493Overall official - principal investigatorN/ANov 1, 2012
- NCT01767493Lead sponsorN/ANov 1, 2012
- NCT01461083Overall official - principal investigatorPhase 1Sep 1, 2011
- NCT01461083Lead sponsorPhase 1Sep 1, 2011
- NCT01461083Reponsible party - principal investigatorPhase 1Sep 1, 2011
- NCT01461109Overall official - principal investigatorPhase 1Aug 1, 2011
Details
- Founded
- New Haven, CT, US Jan 1, 2001
- Last known activity
- May 12, 2025